- Home
- IDR vs RCKT Comparison
IDR vs RCKT Comparison
Compare IDR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | RCKT |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 340.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IDR | RCKT |
|---|---|---|
| Price | $48.73 | $3.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $17.50 | ★ $29.12 |
| AVG Volume (30 Days) | 745.4K | ★ 2.1M |
| Earning Date | 11-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.70 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $35,424,313.00 | N/A |
| Revenue This Year | $55.62 | N/A |
| Revenue Next Year | $23.93 | N/A |
| P/E Ratio | $65.85 | ★ N/A |
| Revenue Growth | ★ 61.35 | N/A |
| 52 Week Low | $10.06 | $2.19 |
| 52 Week High | $54.70 | $12.65 |
Technical Indicators
Market Signals| Indicator | IDR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 59.71 |
| Support Level | $45.40 | $3.36 |
| Resistance Level | $49.26 | $4.05 |
| Average True Range (ATR) | 3.48 | 0.20 |
| MACD | 0.22 | 0.04 |
| Stochastic Oscillator | 78.66 | 66.86 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.